IoT in pharma manufacturing changes company culture

Digital transformation comes with unforeseen yet sometimes very beneficial consequences. Who would have guessed that introducing IoT (Internet of Things) to pharmaceutical manufacturing could have a broader transformational impact on a traditionally conservative company culture?

Conservative Pharma Industry

As a bit of background information, there are many reasons why the pharmaceutical industry tends to be more risk-averse than others. Here are some key considerations:

  • Long-term investment:
    Developing an innovative new drug easily takes 10 years and costs $2.6Bn upfront (according to the Pharmaceutical Research and Manufacturers of America, PhRMA) before the actual product reaches the market. Pharmaceutical development remains a high-cost, high-risk business where mistakes are punished harshly and can ruin a company.
  • Regulated industry
    Regulatory authorities, such as the Food and Drug Administration (FDA) in the United States and corresponding agencies around the world, closely inspect every aspect of the development, manufacturing, and marketing of medicinal drug products from pharma companies. If a company is found out of compliance with Good Manufacturing Practices (GMP), severe financial penalties can be imposed and drastic consequences loom – including shutting down the business altogether.
  • Human lives are at stake
    Pharmaceutical manufacturing is where the rubber hits the road: Any problems in the manufacturing process can easily affect product quality and thereby directly threaten the health and lives of patients. Every facet must be closely observed, and regulatory inspections are frequent and thorough. Therefore, changes to the manufacturing environment are done most reluctantly by companies to minimize risks.

The burden from these limitations weighs heavy on the organization and lends itself to a conservative mindset and cautious approach. Change is not always welcome as it induces risk that could jeopardize operations and outcomes.

Moving to IoT

The Internet of Things (IoT) is more than just a bunch of devises and sensors that communicate with each other and generate a constant stream of data: IoT affects not only how we (make things) work but can also affect how we think and the foundation for our decision-making.

The traditional process in pharmaceutical manufacturing produces batches of product. It requires many human process steps from preparing and calibrating machinery, running the batch, examining the quality and then cleaning and preparing the equipment again for the next batch of the same or an entirely different product. During the process, devices collect data in their own ‑often proprietary‑ data formats that may be hard to access. The data has to be collected, combined and interpreted in a time-consuming process full of interpretation barriers and prone to human error. Even worse, “over 70% of the data in manufacturing is never touched” according to the CEO of Bigfinite, an IoT provider, and certainly not timely. This comes at a cost as this example shows: An American pharma company reportedly lost $20 million worth of product when a $3,500 vacuum pump broke down.

Around 30% of the Top 20 pharma companies started introducing IoT in their pharmaceutical manufacturing (according to GEP, a supply-chain advisory firm) to enable faster and continuous data collection from several processes for real-time monitoring, integrated analytics, and more timely decision-making. The paramount goal was to meet regulatory demand, such as the FDA requirement for continued process verification.

What comes with IoT

However, IoT relies on Cloud computing to provide digital connectivity across the entire supply chain from production to market and across plants. IoT Cloud computing may come with the necessity to use third-party-run servers for data storage and calculations raising the all too familiar fears of pharma managers and employees. Often enough it is the employees who interpret regulatory guidance to narrowly and don’t dare to rock the boat by changing the current GMP (cGMP) out of inflated data security concerns and the doomy risk of falling out of compliance.

While care certainly needs to be taken when implementing the new technology and while processes need to remain compliant, the FDA has already shown flexibility and set a precedence in approving the shift from batch to continuous manufacturing for Johnson&Johnson’s HIV drug PREZISTA.

More recently, the regulatory concern no longer seems paramount. Instead, management understands that IoT opens the door to massive and much-needed cost savings, shorter cycle time, right-sizing operations, increased productivity and higher competitiveness in the highly competitive pharmaceutical market arena.

People transformation beyond digital

Interestingly, all these more technical aspects can distract from how IoT in pharmaceutical manufacturing can lead to a broader shift of mindset throughout the organization:

Sharing and compiling formerly compartmentalized data across different parts of an organizational practically breaks the well-established and well-protected silos in many organizations. Suddenly, everyone seems connected to everyone else in the company and departmental borders fall while the process becomes visible and more transparent in real-time.

The fundamental shift with IoT and Cloud computing forces management and workers to adapt to the new technology and to connect with others outside their immediate organizational silo. The newly integrated informatics can include Enterprise Resource Planning (ERP) and financial systems. Sharing the data trove happens not only within a manufacturing plant but also across 25 plants at Pfizer, for example.

The technology-induced visibility and management of the manufacturing process challenges the traditional mode of operation and encourages employees trying out something new. If managed well, this mindset shift can be used to crack the barriers and drive a favorable cultural change throughout the organization. It enables but also pushes employees to continuously improve manufacturing operations while it also translates and proliferates into all other aspects of their work.

Summary

IoT technology in pharmaceutical manufacturing not only improves the productivity and competitiveness while maintaining regulatory compliance but also challenges and steers employee mindset away from overly conservative restraint toward collaboration and continuous improvement – and thereby shifts the organizational in favorable directions.

Advertisement

Apply for ASHOKA Social Intrapreneurship for Innovation in Health and Wellness 2017

Sign up for this unique professional development opportunity, where health and wellness professionals and social innovators from organizations around the world will come together to innovate in this online course.

Four years ago, I helped to launch the “Social Intrapreneurship for Innovation in Health and Wellness” program of ASHOKA in cooperation with Boehringer Ingelheim.  With overwhelming success, the program was repeated every year since 2014 and is being offered again this year from April 24 thru June 2, 2017!

Who should sign up?

Sign up for this unique professional development opportunity, where health and wellness professionals and social innovators from organizations around the world will come together to innovate in this online course.

What is Social Intrapreneuring?

Social Intrapreneurship is a methodology for cultivating and advancing social innovation within institutions by adopting agile, strategies while building essential skills such as leadership, empathy, teamwork and change-making. This 5th edition of the course is sponsored by the Making More Health initiative – creating a healthier world for individuals, families and their communities through social entrepreneurship and intrapreneurial thinking.

Where do I sign up?

Check out the course sign-up page: http://bit.ly/socintspring2017
Space is limited and based on a first-come, first-served basis. Participants will also be vetted based on criteria and fit for the course. We strongly encourage Boehringer Ingelheim employees, as well as health and wellness social entrepreneurs and professionals to apply.

Course Details
Application Opens: NOW
Application Deadline: April 13th
Course start date: April 24th
Course end date: June 2nd

Expected Time Commitment: 2-3 hr/week time-flexible, self-paced and interactive.

Questions?

If you have any questions about the course, please feel free to email the organizaers at courses@ashoka.org

Meet me at 2017 ISPIM Innovation Forum XXVII- Fostering Innovation Ecosystems

Join my session on “Building a Sustainable Innovation Ecosystem in a Global Corporation” in the Innovation Culture & Ecosystems track on March 21.

Meet me at the International Society for Professional Innovation Management (ISPIM) Conference 2017 ISPIM Innovation Forum XXVII- Fostering Innovation Ecosystems in Toronto, Canada on March 19-22, 2017!

Join my session on “Building a Sustainable Innovation Ecosystem in a Global Corporation” in the Innovation Culture & Ecosystems track on March 21.

Blog ISPIM Toronto event picture

 

What my session is about?

Large pharmaceutical (and other) organizations struggle with the tectonic shifts and fundamental changes across the landscapes worldwide. The traditional mindset and business models are failing. A rejuvenating and holistic transformation effort is needed to get nimble again and adapt to the new reality.
How do you change a stagnant innovation culture and create a sustainable ecosystem within a global organization that stands the challenges of real life?
As an example, this case study discusses the comprehensive yet practical approach that mobilized hidden talent and resources transforming Boehringer Ingelheim, a Global FORTUNE 500 pharmaceutical company, from within on a global scale. It generated exponential returns and fundamentally changed the culture of the organization from leadership training and managerial decision-making down to bringing grass-root ideas to a break-through and new career paths for employees.

What is the Problem?

The issue is universal and not limited to a pharmaceutical or healthcare company: There is no lack of great ideas aiming beyond incremental improvement at the grassroots of large organizations. There is also no lack of funds or support for break-through ideas on the top of the hierarchy; in fact, leadership is constantly seeking for good ideas. However, there are many obstacles bringing them together.
One problem is how to connect the people with great, disruptive ideas with the ones that have the authority and resources to making them happen in the organization?
A second problem is how to find and vet the ideas that have a game-changing potential and develop them with limited risk?
The third problem is that even with executive support it can be hard to implement a new idea against the resistance of the organization, which rejects them as disrupting the equilibrium of the status quo.
The proposed session illustrates and discusses the real-life experiences of building and operating a holistic and sustainable framework that successfully addressed the issue, overcame resistance on many levels, and yielded an exponential return-of-investment. It resulted in a visible and measurable way changed innovation mindset and changed behaviors throughout the organization to bring disruptive ideas and projects to life.

Where do I find more Information on the Topic?

Visit my blog OrgChanger.com to read more about intrapreneuring with case studies and real-life success stories!

Rethink Healthcare – Workshop – Berlin, Germany – April 11, 2017 #rethinkhealthcare17

Sign up for RETH!NK HEALTHCARE! – Big Data, Augmented Reality, Wearables
and visit my workshop “Digitale Disruption im Gesundheitssystem: Was sind die Risiken und Chancen für Pharmaunternehmen?” in the heart of Berlin, Germany, on April 11, 2017! – Follow the event on Twitter #rethinkhealthcare17

speaker

 

How to become a “Partner of Choice”? (Article)

Expert advice on open innovation from executives with experience at Bayer, Lilly and Boehringer Ingelheim published in the December/January 2017 issue of the Healthcare Sales & Marketing Magazine (HS&M) e-magazine:

How to become a Partner of Choice (.pdf)

Join Executive Round Table event: “The innovation and technology convergence in Life Science and Healthcare industry”

With improved technology, especially, Artificial Intelligence, what physicians will be needed in the future?
Join the Executive Round Table event on Nov. 22, 2016 featuring “The innovation and technology convergence in Life Science and Healthcare industry”

Life Science Quest and the Sino-American Pharmaceutical Professionals Association, Connecticut (SAPA-CT) work together bringing a series of high-level professional and business development events to Life Science and Health Care industry in the TriState Metropolitan area, providing high level business networking, round tables discussions and business seminars. 

This joint event of Life Science Quest and SAPA-CT in the Life Science & Healthcare series is to be held 22 November 2016 6:00 PM at Mount Saint Mary College  (330 Powell Avenue, Newburgh, NY. Aquinas Hall room 163).

Eyeforpharma on Open Innovation – How to become a ‘Partner of Choice’?

The Art of Innovation: How to Become a “Partner of Choice” is an insightful interview with seasoned innovation professionals discussing what it takes to build a Partner-of Choice-relationship with Open Innovation in the pharmaceutical industry.

The Art of Innovation: How to Become a “Partner of Choice” is an insightful interview with seasoned innovation professionals discussing what it takes to build a Partner-of Choice-relationship with Open Innovation in the pharmaceutical industry.

Join me at Singularity University’s first Germany Summit, Berlin, 20-21.Apr.16

Join me at Singularity University’s first Germany Summit, Berlin, 20-21.Apr.16

On April 20-21, 2016, Singularity University, the most innovative and forward-looking institution, has chosen to host their SingularityU Germany Summit in Berlin—one of the most vibrant cities in the world. SingularityU Germany Summit is a local Chapter and community organization of Singularity University. It is one of the largest two-day events in Europe aimed at bringing awareness about exponential technologies and their impact on business and policy to thought leaders and executives from breakthrough companies.

What can you expect at SingularityU Germany Summit?

Leading experts from the global high-tech community will present the latest trends and cutting-edge developments in Mobility, Organization, Manufacturing, Artificial Intelligence, Computing, Robotics, 3D Printing, Machine Learning and Design Thinking. Together we strive to inspire and empower European leaders and influencers in using exponential technologies to solve today’s most pressing issues. SingularityU Germany Summit is an ideal platform to network for both alumni as well as first time attendees, leaders, government representatives, entrepreneurs, investors, NGOs.

500 attendees ranging from CEOs to young innovators from across the globe are expected to attend the event. Together we will explore issues such as: How can technological evolution be transformed into a sustainable and value-based growth for any industry? What ethical standards and responsibilities do global leaders have to account for?

 

 

 

 

Digital Transformation at ‘Life-Science meets Telco7’ on April 14, 2016

Meet me in Bonn, Germany on April 14, 2016 for the 7th installation of DeTeCon’s Life-Science meets Telco series.

This year‘s event focuses on a very special aspect of the Digital Transformation – the cross-industry collaboration and exchange.

How can digitalization be implemented to make a difference in every patient’s life? What best practices from other industries can be transferred to the pharmaceutical and healthcare industries? These and many more questions we will answer at this year’s event.

You can expect a great atmosphere for networking as well as exciting discussions on:

  • What is the role of the Digital Transformation for Pharma?
  • Importance of the collaboration between Life Sciences & ICT: current changes in ICT.

Don’t miss this opportunity! Save the date and stay tuned for more information!

 

Join Masterclass webinar: “Beyond-the-Pill” Disruptive Innovation within Pharma, Feb. 23, 2016

The pharmaceutical industry struggles with the fundamental changes of the healthcare systems worldwide. For many reasons, the traditional mindset and business models of the past are failing today. New approaches are needed for innovation “beyond the pill” to stay profitable and ahead of competitors.

But how to change a large organization bottom up and from within?

Sign up for the Masterclass: “Beyond-the-Pill” Disruptive Innovation within the Pharmaceutical Industry webinar hosted by the Intrapreneurship Conference at 5-7pm CET (11am-1pm ET) on February 23, 2016!

Intrapreneurship Conference

Why?  The pharmaceutical industry struggles with the fundamental changes of the healthcare systems worldwide. For many reasons, the traditional mindset and the business models of the past are failing. New approaches are needed for innovation “beyond the pill” to stay profitable and ahead of competitors.

But how to change a large organization bottom up and from within?

This session offers you a unique birds-eye and worms-eye view on pharma innovation and its shortcomings under the current paradigm, before diving into real-life case studies of intrapreneuring, disruptive transformation and strategic innovations within and beyond a Global FORTUNE 500 pharma company.

Join this masterclass and learn on how to bring intrapreneuring and transformation to life in a large pharma company.

Driving Innovation in Healthcare: New Executive Intrapreneuring Workshop

Experience the new two-day intrapreneurial journey to transform you organization with exponential results!

Don’t miss EBCG’s intense and hands-on Intrapreneuring Workshop “Building an innovation framework to design, launch and execute business projects” in the Driving Innovation in Healthcare series in the “Golden City” of Prague, Czech Republic, on April 6-7, 2016.

Sign up before December 23, 2015, to save during the special promotion period.


 

 

Join my Online Workshop on Project and Portfolio Management in Pharma, Dec. 10, 2015 @OrgChanger

Join my Workshop at the European Project & Portfolio Management in the Pharmaceutical Industry online conference from 2:00 – 5:30 PM CET on December 10, 2015.

This workshop-based online conference (see how an online conference works) serves as an interactive platform designed to assist industry professionals involved in project and portfolio management in acquiring practical skills and knowledge.

Infographic_Project and Portfolio in Pharma

The Future of Pharma: Calls Moving to Consults (video)

Calls Moving to Consults is a thought leadership video in the “10 Inevitable Changes in Pharma 2015” series that was hosted by the stellar Richie Etwaru, Chief Digital Officer with Cegedim.

This video addresses the question:  How can the pharmaceutical industry reskill representatives to be knowledgeable consultants to physicians?

Today, sales expertise is not enough. The pharmaceutical representative needs to be a broker of information. Physicians now have very limited time – and dictate when they can meet with representatives, from whom they need comprehensive information that they can pass along to their increasingly educated patients.

In this video, Jo Ann Saitta, Chief Digital Officer of the CDM Group, Stephan Klaschka, Innovation and Healthcare Consultant, and moderator, Richie Etwaru, Chief Digital Officer at Cegedim, examine this shift and the challenges pharmaceutical companies may face in properly retraining their people. These challenges include: adopting a culture of learning agility; integrating silos of information; having the ability to serve up dynamic content; and training representatives to utilize technologies that will maximize their brief but demanding visits with physicians.

Use this link to watch all 10 videos in the series on YouTube directly – enjoy!

  • 10 Inevitable Changes in Pharma 2015 – Communication moving to Collaboration
    • Angela Miccoli
    • Wendy Mayer
  • 10 Inevitable Changes in Pharma 2015 – Content moving to Context
    • James Corbett
    • Craig DeLarge
  • 10 Inevitable Changes in Pharma 2015 – Care moving to Cure
    • Michael DePalma
    • John Nosta
  • 10 Inevitable Changes in Pharma 2015 – Compliance moving to Culture
    • Bill Buzzeo
    • Gus Papandrikos
  • 10 Inevitable Changes in Pharma 2015 – Supply Chains moving to Supply Constellations
    • Ray Wang
    • Aron Dutta
  • 10 Inevitable Changes in Pharma 2015 – Customization moving to Configuration
    • Tracy Maines
    • Krishna Cheriath
  • 10 Inevitable Changes in Pharma 2015 – Customer moving to Consumer
    • Paul Kandle
    • Mark Stevens
  • 10 Inevitable Changes in Pharma 2015 – Calls moving to Consults
    • Jo Ann Saitta
    • Stephan Klaschka
  • 10 Inevitable Changes in Pharma 2015 – Cloud moving to Crowd
    • Les Jordan
    • Krishnan Sridharan
  • 10 Inevitable Changes in Pharma 2015- Charity moving to Cause
    • Janet Carlson
    • Beth Bengtson
%d bloggers like this: